Establishment Labs (NASDAQ:ESTA) Stock Price Down 5.6% - Here's What Happened

Key Points

• Establishment Labs' stock price decreased by 5.6%, closing at $39.33 after trading as low as $39.22 on Thursday, with trading volume down by 80% from average levels.
• Brokerages have recently updated their ratings, with Citigroup raising its price target to $47.00 and Mizuho increasing it to $70.00, indicating a general optimistic outlook as five analysts issued a "Buy" rating.
• The company reported a loss of ($0.57) earnings per share for the last quarter, missing expectations, while revenue increased 16.1% from the previous year, totaling $51.30 million.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) shares fell 5.6% during trading on Thursday . The company traded as low as $39.22 and last traded at $39.33. 99,948 shares traded hands during trading, a decline of 80% from the average session volume of 492,797 shares. The stock had previously closed at $41.66.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ESTA. Citigroup upped their price objective on Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 9th. Wall Street Zen raised Establishment Labs from a "sell" rating to a "hold" rating in a research note on Saturday, September 20th. Mizuho increased their price target on Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Needham & Company LLC reiterated a "buy" rating and issued a $48.00 price target on shares of Establishment Labs in a research report on Friday, June 13th. Finally, Canaccord Genuity Group started coverage on Establishment Labs in a research note on Wednesday, August 20th. They issued a "buy" rating and a $60.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Establishment Labs presently has an average rating of "Moderate Buy" and a consensus price target of $56.50.

Establishment Labs Trading Down 7.0%

The company has a 50 day moving average of $40.08 and a 200 day moving average of $37.89. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 9.71. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -12.77 and a beta of 0.85.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). The business had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.80 million. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The company's revenue for the quarter was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.62) EPS. Establishment Labs has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp boosted its position in shares of Establishment Labs by 53.9% during the fourth quarter. Northern Trust Corp now owns 28,165 shares of the company's stock worth $1,298,000 after buying an additional 9,865 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Establishment Labs by 15.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,658 shares of the company's stock valued at $2,196,000 after buying an additional 6,307 shares during the period. Toronto Dominion Bank bought a new position in shares of Establishment Labs during the fourth quarter worth approximately $24,879,000. Patriot Financial Group Insurance Agency LLC bought a new position in shares of Establishment Labs during the first quarter worth approximately $234,000. Finally, Elevation Point Wealth Partners LLC acquired a new position in Establishment Labs in the 1st quarter valued at $207,000. 72.91% of the stock is owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.